(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 March 2009 (05.03.2009)

PCT

(10) International Publication Number
WO 2009/027745 A1

(51) International Patent Classification:
A61K 9/20 (2006.01) *A61K 9/50* (2006.01)

(21) International Application Number:
PCT/GB2008/050755

(22) International Filing Date: 29 August 2008 (29.08.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/969,188 31 August 2007 (31.08.2007) US

(71) Applicant *(for all designated States except MG, US)*: **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(71) Applicant *(for MG only)*: **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London, Greater London W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ABRAHAMSSON, Bertil, Sven, Inge** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **ABRAHMSÉN ALAMI, Susanna, Johanna** [SE/SE]; AstraZeneca R & D Lund, S-221 87 Lund (SE). **BAGGER-JÖRGENSEN, Håkan, Lars** [SE/SE]; AstraZeneca R & D Lund, S-221 87 Lund (SE). **CULLBERG, Marie, Christine, Sindeby** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **HJÄRTSTAM, Lars, Johan, Pontus de Verdier** [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **NILSSON, Susanne, Anette** [SE/SE]; AstraZeneca R & D Lund, S-221 87 Lund (SE).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY**; AstraZeneca AB, S-151 85 Södertälje (SE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

(54) **Title:** PHARMACEUTICAL FORMULATION FOR EXTENDED RELEASE

Figure 3 : Mean plasma concentration of Compound A (µmol/L) versus time (hr) after a single dose of 500mg administered as IR or ER tablets with tolbutamide and midazolam (n=24)




Figure 3

Compound A = Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(OMe)

(57) **Abstract:** An extended release pharmaceutical formulation comprising, as active ingredient, the compound Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(OMe) or a pharmaceutically acceptable salt thereof (such as a sulfonic acid salt, such as the benzenesulfonic acid 5 (besylate) salt); and a pharmaceutically acceptable diluent or carrier; for use in providing a therapeutic anti-thrombotic effect whilst limiting drug-drug interactions with other concomitantly dosed drug/s, particularly those which are metabolised by CYP-450 enzymes.

WO 2009/027745 A1